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Background
The cyclic nucleotide second messengers cAMP and cGMP
play key roles in mammalian signal transduction. Their
intracellular levels are tightly controlled by the rate of syn-
thesis and degradation. Hydrolysis of the cyclic nucle-
otides is dependent on the activity of phosphodiesterases
(PDE) of which to date 11 families have been identified.
The cGMP-stimulated cGMP/cAMP phosphodiesterase 2
is encoded by one gene, which has been shown to be
spliced into three variants that have been cloned from dif-
ferent species. Besides the ubiquitous soluble PDE2A1,
two membrane associated forms, PDE2A2 and PDE2A3,
have been described. The PDE2A splice variants only dif-
fer in short stretches of amino acids at their very N termi-
nus. This region has previously been suggested to
determine the subcellular localization of the enzyme, but
data about the mechanism underlying membrane attach-
ment of PDE2A3 are lacking.
Results
Here, we show that concurrent myristoylation and palmi-
toylation targets PDE2A3 to synaptic membranes. In met-
abolic labeling studies, PDE2A3 incorporated
3[H]myristate, whereas mutation of the myristoyl recipi-
ent Gly2 prevented radiolabeling. Additionally, and in
contrast to the wild type enzyme, the non-myristoylated
mutant was completely soluble when expressed in
HEK293 or PC12 cells. As myristoylation alone is rarely
sufficient for stable membrane attachment of proteins,
the cysteines 5 and 11 as possible candidates for palmi-
toylation were also mutated. This partially solubilized the
enzyme and led to an accumulation in the ER/Golgi com-
partment, as shown by fluorescence microscopy. By gen-
erating isoform-specific antibodies, we were able to
confirm on the protein level the widespread expression of
the soluble PDE2A1 in mouse tissues. More importantly,
we demonstrate for the first time that PDE2A3 is predom-
inantly expressed of in mouse brain where it is attached to
synaptosomal membranes. In primary cultures of hippoc-
ampal neurons an expression pattern overlapping with
synaptophysin was observed, suggesting a presynaptic
localization.
Conclusion
Our results suggest that the neuronal PDE2A3 is dually
acylated and thereby targeted to synaptic ends, where
PDE2A3 can mediate interplay between cAMP and cGMP
dependent signaling pathways.
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